Business Divisions

MorphoSys’s strategy is aimed at exploiting its proprietary technologies in two areas, namely therapeutic and research antibodies.

Therapeutic Antibodies Segment

The Therapeutic Antibodies segment comprises MorphoSys’s activities in the area of therapeutic antibodies, which includes its therapeutic antibody collaborations with pharmaceutical and biotech companies as well as own antibody development programs.

Research Antibodies Segment (AbD)

The Research Antibodies segment comprises all activities of MorphoSys’s Research and Diagnostics Antibodies unit. From 2006 onwards, the segment will be named AbD - Antibodies Direct. The AbD segment will comprise all activities of Antibodies by Design and Biogenesis as well as the Serotec Group, which was acquired in January 2006.